Could not disagree with you more and here is why...
The reason for that is because in that his last news release Maresky announced the appointment of Dr.Joseph Wagner as the president and CEO of BCT and since then Dr.Wagner has issued all the releases.Is it not normal for the CEO and Chairman of the Board to issue news releases? It was a positive step forward for BCT and not the negative you made it out to be.I also reiterate my statement that Maresky has sold ZERO shares so any reference to "cashing in" would certainly not apply.
Facts are important when posting public opinions about companies. We should strive to make certain they are correct. SH rules do not apply at SI.
BriaCell appoints Wagner CEO, Babaei chairman
2015-06-01 08:14 MT - News Release
Mr. Isaac Maresky reports
BRIACELL THERAPEUTICS ANNOUNCES NEW PRESIDENT, CEO AND CHAIRMAN OF THE BOARD
BriaCell Therapeutics Corp. has appointed Dr. Joseph Wagner, PhD, as president and chief executive officer of the company, effective today. Dr. Wagner comes to BriaCell following his resignation as president and CEO of OncoCyte Corp., a subsidiary of BioTime Inc., a publicly listed company on the New York Stock Exchange.
The company is also delighted to appoint biotech veteran Dr. Saeid Babaei as its chairman of the board of directors. Dr. Joseph Wagner is a proven, reputable CEO and an expert scientist, and the company believes that he has the depth and expertise to substantially advance and grow its current technology as well as expand its platform. Dr. Wagner has launched, managed and sold biotech companies, the named inventor on multiple patents, and has lectured and trained at top medical institutions. The company is also delighted to appoint biotech veteran Dr. Saeid Babaei as its chairman of the board of directors, which will allow the company's visionary founder, Dr. Charles Wiseman, to focus on company's clinical development program as chief medical officer. This structuring, with a professional full-time CEO and an independent non-officer chairman, is intended to position the company more in line with its biotech peers on larger stock exchanges.
Dr. Babaei commented: "Simply put, we believe Dr. Wagner possesses the skillsets to take BriaCell to the next level. He is a seasoned executive but also a PhD scientist who has invented technologies and grown biotechs from launch all the way to acquisition. Investors entrusted us to build out a top-calibre team, and in my mind Dr. Wagner is the ideal CEO to take BriaCell through its next phase of growth, a respected executive with both a scientific background, as well as deep relationships with large American pharma companies and institutional capital markets. Dr. Wagner has a vast network of top biotech investors, including many who have backed him in the past. We believe that having someone of Dr. Joseph Wagner's calibre working and marketing BriaCell 24/7, will prove to be highly valuable for investors."
"I am thrilled and honoured to be joining BriaCell," said Dr. Wagner. "I have studied BriaCell's clinical data in depth, and I believe the technology invented by Dr. Wiseman and being developed at BriaCell holds tremendous potential. I have seen many technologies, some more advanced than BriaVax, but in my mind BriaCell has achieved truly unique results and presents real growth opportunity. I am fully committed to BriaCell and will bring all my relationships to bear in ensuring success. I look forward to initiating our upcoming clinical trial as well as strategically building the company into a leading developer of cancer immunotherapy."
Dr. Wagner was the president of Cell Targeting Inc., a company which was acquired by a subsidiary of BioTime. After the acquisition, Dr. Wagner became the president and CEO of OncoCyte, where he developed, initiated and managed multiple clinical trials in oncology with a total patient enrolment of over 2,000 patients, including programs in breast, bladder and lung cancers. Prior to this, Dr. Wagner was a senior director of research and development at Neuronyx, where he worked directly under its founder, Dr. Hubert J.P. Schoemaker, considered by many to be one of the pioneers of biotech. After Dr. Schoemaker's passing, Dr. Wagner became vice-president of Neuronyx, responsible for its cell therapy division.
During Dr. Wagner's academic career, he was an associate professor for nearly five years at the Karolinska Institute, where he focused on molecular neurobiology and developed technologies which led to six patent applications. The Karolinska Institute was recently ranked amongst the top-10 medical universities in the world, and its famed Nobel Assembly is responsible for awarding the Nobel Prize in physiology or medicine. Dr. Wagner completed his PhD at Duke University, where he specialized in pharmacology, and he is the named inventor on patents in the cell therapy and oncology fields.
We seek Safe Harbor. |
